Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
There is an upward development for Pacira Pharmaceuticals compared to yesterday, with an increase of €0.40 (1.690%).
With 15 Buy predictions and not the single Sell prediction the community is currently very high on Pacira Pharmaceuticals.
With a target price of 50 € there is potential for a 108.33% increase which would mean more than doubling the current price of 24.0 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 1.690% | -0.826% | -8.397% | -39.698% | -19.463% | -54.286% | -31.799% |
| Gritstone Oncology Inc | 0.200% | 11.232% | -68.609% | -64.385% | -58.692% | -90.478% | - |
| Avid Bioservices Inc | 5.380% | 15.126% | 7.031% | -56.090% | 12.295% | -61.517% | 57.743% |
| Endo International | - | 0.000% | 400.000% | -85.714% | -75.000% | -99.798% | -99.848% |
Comments
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $45.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat